Regulating HIF-2α stabilization with an intelligent switchable nanoplatform for tumor immunity reprogramming and enhanced therapy
Source abstract
Abstract
Chronic hypoxia is a critical barrier to the effective treatment of solid tumors, including hepatocellular carcinoma (HCC), as it not only restricts the oxygen supply required for sonodynamic therapy (SDT) but also upregulates hypoxia-inducible factor-2α (HIF-2α), thereby accelerating tumor progression, inducing abnormal angiogenesis, suppressing antitumor immune responses, and diminishing the efficacy of targeted therapies. Here, we developed an intelligent switchable organic-inorganic hybrid nanoplatform (VitK3/P-Ce6@H-MnO2) that integrates oxygen self-supply, reactive oxygen species (ROS) storm induction, and immune microenvironment reprogramming. The acidic tumor microenvironment serves as an "endogenous switch," triggering the decomposition of H-MnO2 to release oxygen and Vitamin K3, thereby alleviating chronic hypoxia, facilitating HIF-2α degradation, and providing oxygen support for Ce6-mediated SDT. Upon ultrasound exposure as an "exogenous switch," activated Ce6, together with Vitamin K3 and Mn2+, induces a robust ROS storm, resulting in mitochondrial dysfunction and immunogenic cell death (ICD), while effectively reprogramming the chronic hypoxia-HIF-2α-driven immunosuppressive tumor microenvironment. Furthermore, in vivo studies demonstrated that Lenvatinib therapy, when combined with the nanoplatform, further suppressed chronic hypoxia-HIF-2α-driven abnormal angiogenesis, enhanced CD8+ T-cell infiltration, and boosted antitumor immune responses, ultimately achieving a potent synergistic therapeutic effect and promoting the conversion of "cold tumors" into "hot tumors." This study provides strong experimental evidence that nanoplatform-mediated immune microenvironment reprogramming represents a precisely controllable and highly effective therapeutic strategy for solid tumors, with promising translational potential in hepatocellular carcinoma.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism · Cancer Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (54)
Show source-provided references
1. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy10.1038/s41571-023-00825-3 ↗
2. Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries
3. The lancet commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment10.1016/S0140-6736(25)01042-6 ↗
4. Hypoxia is a key regulator in liver cancer progression10.1016/j.jhep.2021.05.032 ↗
5. Hypoxia-driven immunosuppression by treg and type-2 conventional dendritic cells in hcc10.1002/hep.32419 ↗
6. Recent advances and future directions in sonodynamic therapy for cancer treatment10.34133/bmef.0080 ↗
7. An oxygen-generating nanoplatform remodels the immunosuppressive tumor microenvironment via synergistic lactate depletion and sonodynamic therapy10.1186/s12951-025-03524-6 ↗
8. Easl clinical practice guidelines on the management of hepatocellular carcinoma10.1016/j.jhep.2024.08.028 ↗
9. Synergistic sdt/cuproptosis therapy for liver hepatocellular carcinoma: enhanced antitumor efficacy and specific mechanisms10.1186/s12951-024-02995-3 ↗
10. The tumor microenvironment in hepatocellular carcinoma: mechanistic insights and therapeutic potential of traditional chinese medicine10.1186/s12943-025-02378-8 ↗
11. Redefining the role of hypoxia-inducible factors (hifs) in oxygen homeostasis10.1038/s42003-025-07896-1 ↗
12. Empowering hypoxia to convert cold tumors into hot tumors for breast cancer immunotherapy10.1038/s41420-025-02682-8 ↗
13. The transition from hif-1 to hif-2 during prolonged hypoxia results from reactivation of phds and hif1a mrna instability10.1186/s11658-022-00408-7 ↗
14. Hypoxia, oxidative stress, and the interplay of hifs and nrf2 signaling in cancer10.1038/s12276-024-01180-8 ↗
15. Differential but complementary roles of hif-1alpha and hif-2alpha in the regulation of bone homeostasis10.1038/s42003-024-06581-z ↗
16. Siah2 regulates stability of prolyl-hydroxylases, controls hif1alpha abundance, and modulates physiological responses to hypoxia10.1016/j.cell.2004.06.001 ↗
17. Deletion of prolyl hydroxylase domain-containing enzyme 3 (phd3) in zebrafish facilitates hypoxia tolerance10.1016/j.jbc.2023.105420 ↗
18. Oxygen-dependent changes in binding partners and post-translational modifications regulate the abundance and activity of hif-1alpha/2alpha10.1126/scisignal.abf6685 ↗
19. Nanosonosensitizers with ultrasound-induced reactive oxygen species generation for cancer sonodynamic immunotherapy10.3389/fbioe.2021.761218 ↗
20. A hypoxia responsive nanoassembly for tumor specific oxygenation and enhanced sonodynamic therapy10.1016/j.biomaterials.2021.120822 ↗
21. Cold and hot tumors: from molecular mechanisms to targeted therapy10.1038/s41392-024-01979-x ↗
22. Transforming the "cold" tumors to "hot" tumors: strategies for immune activation10.1016/j.bcp.2025.117194 ↗
23. The tumor epr effect for cancer drug delivery: current status, limitations, and alternatives10.1016/j.addr.2022.114614 ↗
24. Stealth nanoparticles in oncology: facing the peg dilemma10.1016/j.jconrel.2022.09.002 ↗
25. Cancer-responsive multifunctional nanoplatform based on peptide self-assembly for highly efficient combined cancer therapy by alleviating hypoxia and improving the immunosuppressive microenvironment10.1021/acsami.2c20388 ↗
26. Hollow manganese dioxide nanoparticles for drug delivery and imaging10.1021/acsanm.4c02040 ↗
27. Inhibition of siah2 ubiquitin ligase by vitamin k3 (menadione) attenuates hypoxia and mapk signaling and blocks melanoma tumorigenesis10.1111/j.1755-148X.2009.00628.x ↗
28. Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through hif/hey1/pink1 pathway10.1038/s41419-019-2155-3 ↗
29. Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency10.1002/advs.202201734 ↗
30. Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-pd-1/pd-l1 for residual tumors immunotherapy after rfa10.1186/s12951-023-02067-y ↗
31. Cox-2/pge2 axis regulates hif2alpha activity to promote hepatocellular carcinoma hypoxic response and reduce the sensitivity of sorafenib treatment10.1158/1078-0432.CCR-17-2725 ↗
32. Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives10.1038/s41392-025-02249-0 ↗
33. The hif axes in cancer: angiogenesis, metabolism, and immune-modulation10.1016/j.tibs.2025.06.005 ↗
34. Hypoxia-induced vegf enhances tumor survivability via suppression of serum deprivation-induced apoptosis10.1038/sj.onc.1203814 ↗
35. Endothelial cell apoptosis in angiogenesis and vessel regression10.1007/s00018-017-2577-y ↗
36. The role of vegf in cancer-induced angiogenesis and research progress of drugs targeting vegf10.1016/j.ejphar.2023.175586 ↗
37. The bcl-2 protein family: opposing activities that mediate cell death10.1038/nrm2308 ↗
38. Nanomedicine in cancer therapeutics: current perspectives from bench to bedside10.1186/s12943-025-02368-w ↗
39. Stromal hif2 regulates immune suppression in the pancreatic cancer microenvironment10.1053/j.gastro.2022.02.024 ↗
40. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions10.1038/s41392-023-01332-8 ↗
41. Targeting hif-2alpha in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade10.1007/s00018-025-05642-8 ↗
42. Tumor-targeting nanomaterials based on metal-organic frameworks mediate tumor immunotherapy by promoting cuproptosis and pyroptosis in hepatocellular carcinoma cells
43. Tumor vascular occlusion by calcium-based thermosensitizer provokes continuous cavitation effect and thermal energy transition efficiency of radiofrequency ablation therapy10.1016/j.biomaterials.2024.122944 ↗
44. Bimetallic ca/zn nanoagonist remould the immunosuppressive hepatocellular carcinoma microenvironment following incomplete microwave ablation via pyroptosis and the sting signaling pathway10.1002/advs.202500670 ↗
45. Aasld practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma10.1097/HEP.0000000000000466 ↗
46. Systemic therapy for advanced hepatocellular carcinoma: Asco guideline update10.1200/JCO.23.02745 ↗
47. Angiogenic signaling pathways and anti-angiogenic therapy for cancer10.1038/s41392-023-01460-1 ↗
48. Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives10.1186/s13045-024-01647-1 ↗
49. Lenvatinib recruits cytotoxic gzmk+cd8 t cells in hepatocellular carcinoma10.1097/HC9.0000000000000209 ↗
50. Lenvatinib enhances antitumor immunity by promoting the infiltration of tcf1(+) cd8(+) t cells in hcc via blocking vegfr210.1111/cas.15719 ↗
51. Hypoxia-responsive ppargc1a/bambi/acsl5 axis promotes progression and resistance to lenvatinib in hepatocellular carcinoma10.1038/s41388-023-02665-y ↗
52. Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation10.1038/s41401-022-01021-2 ↗
53. Lenvatinib in hepatocellular carcinoma: resistance mechanisms and strategies for improved efficacy10.1111/liv.15953 ↗
54. The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors10.1007/s12032-021-01503-z ↗